Page 21 - Celcuity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Celcuity (Celcuity: CELC) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers.

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE 11 May 2021, 06:05 GMT+10 Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine therapy for patients with ER+/HER2- metastatic breast cancer, in which gedatolisib showed a potentially differentiated safety and tolerability profile Secured additional financing to streng...

Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open) Insmed Incorporated (NASDAQ: INSM) (before the market open) Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open) Endo International plc (NASDAQ: ENDP) (before the market open) Bio-Techne Corporation (NASDAQ: TECH) (before the market open) Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) Athenex, Inc. (NASDAQ: ATNX) (before the market open) Zoetis Inc. (NYS...

ShockWave Medical, Inc. (NASDAQ: SWAV) Verastem, Inc. (NASDAQ: VSTM) Down In The Dumps Akoya Biosciences, Inc. (NASDAQ: AKYA) Decibel Therapeutics, Inc. (NASDAQ: DBTX) IRadimed Corporation (NASDAQ: IRMD) Lucira Health, Inc. (NASDAQ: LHDX) Mesoblast Limited (NASDAQ: MESO) Protara Therapeutics, Inc. (NASDAQ: TARA) PTC Therapeutics, Inc. (NASDAQ: PTCT) Stocks In Focus Adverum Shares Sink On Serious Adverse Event  Adverum Biotechnologies, Inc. (NASDAQ: ADVM) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its IN...

Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the first quarter 2021 after the stock market close on Monday, May 10, 2021. Management will host a webcast/conference call the same day at 4:30 p.m. Eastern Time (ET) to discuss the results. Webcast Presentation and Conferen...